Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Enhancing Community Understanding of Cancer Clinical Trials Through Peer Education.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026

Same author

Cancer-Associated Thromboembolic Disease and the Evolution of Management.

Cardiology in review·2025

Same author

Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).

Annals of surgical oncology·2025

Same author

An Interesting Case of Hemophagocytic Lymphohistiocytosis in a Postpartum Female With Recent COVID-19 Vaccination.

Case reports in medicine·2024

Same author

Exploring health disparities in diagnosing multiple myeloma.

Expert review of hematology·2024

Same author

Characterizing "collateral damage" in men and women with metastatic breast cancer (mBC) from diverse racial and ethnic backgrounds in New York City.

Breast cancer research and treatment·2024

Search research articles

Related Experiment Video

Updated: Jun 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Inflammatory Breast Cancer and Transient Complete Radiographic Response to Chemoimmunotherapy: A Case Report.

Adina Amin¹, Sasis Sirikanjanapong², Amardeep Kalsi^1,3

¹Department of Internal Medicine, New York-Presbyterian Brooklyn Methodist Hospital Brooklyn, Brooklyn, NY, USA.

Case Reports in Oncology

|October 30, 2024

Summary

This summary is machine-generated.

Inflammatory breast cancer is aggressive. Pembrolizumab with chemotherapy showed a short-lived response in a metastatic triple-negative case, highlighting poor survival despite treatment.

Keywords:

Immunotherapy Inflammatory breast cancer Triple negative breast cancer

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Jun 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Area of Science:

Oncology
Immunotherapy
Breast Cancer Research

Background:

Inflammatory breast cancer (IBC) is a rare, aggressive subtype with poor survival.
Metastatic IBC has high rates of lymph node involvement and distant metastasis.
Pembrolizumab is approved for early and advanced triple-negative breast cancer (TNBC) based on PD-L1 status.

Observation:

A 46-year-old female with de novo metastatic inflammatory TNBC presented with widespread metastasis.
Treatment with pembrolizumab, carboplatin, and paclitaxel induced a rapid, complete radiographic response.
The response was transient, followed by rapid disease progression and death.

Findings:

Metastatic inflammatory TNBC treatment with pembrolizumab and chemotherapy yielded a robust but short-lived response.
Despite initial treatment success, the patient experienced diffuse progression and succumbed to respiratory failure.
This case highlights the limited reported data on immunotherapy response in metastatic inflammatory TNBC.

Implications:

Metastatic IBC treatment strategies require further investigation.
Understanding the mechanisms behind short-lived responses to immunotherapy in IBC is crucial.
Improved therapeutic approaches are needed to enhance survival for patients with inflammatory breast cancer.